Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors' response.
Journal
The Journal of antimicrobial chemotherapy
Journal Volume
79
Journal Issue
12
Start Page
3360
End Page
3361
ISSN
1460-2091
Date Issued
2024-12-02
Author(s)
SDGs
Type
editorial